A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
The Frequency of Optimal Glycemic Control After Adding Sitagliptin on Treatment Regimen of Patient With Type 2 Diabetic
2021
Jundishapur Journal of Medical Sciences
and Objectives Dipeptidyl peptidase-4 inhibitors (DPP4-I) including sitagliptin is a new therapeutic class of oral anti-hyperglycemic drugs for T2DM. The aim of this study was to evaluate the frequency of glycemic control after adding sitagliptin on treatment regimen of patient with type 2 diabetic. Subjects and Methods This cross-sectional study conducted on 120 patients with type 2 diabetes mellitus referring to diabetes clinic of Imam Hospital, Ahvaz in 2019-2020. Sitagliptin (100 mg/day)
doi:10.32598/jsmj.20.4.2324
fatcat:dn73si635fgiloqibdlgaw6et4